SAB Biotherapeutics says FDA grants Fast Track designation for SAB-142 in stage 3 type 1 diabetes

• FDA granted Fast Track designation to SAB Biotherapeutics’ SAB-142 for new-onset Stage 3 type 1 diabetes.
• Candidate is in the registrational Phase 2b SAFEGUARD study, with enrollment expected to finish in Q4 2026.
• Topline data are anticipated in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130830PRIMZONEFULLFEED9844062) on October 13, 2026, and is solely responsible for the information contained therein.